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http://dx.doi.org/10.1016/j.ccr.2012.09.015SUMMARYD-cyclins represent components of cell cycle machinery. To test the efficacy of targeting D-cyclins in cancer
treatment, we engineeredmouse strains that allow acute and global ablation of individual D-cyclins in a living
animal. Ubiquitous shutdown of cyclin D1 or inhibition of cyclin D-associated kinase activity in mice bearing
ErbB2-driven mammary carcinomas triggered tumor cell senescence, without compromising the animals’
health. Ablation of cyclin D3 in mice bearing Notch1-driven T cell acute lymphoblastic leukemias (T-ALL)
triggered tumor cell apoptosis. Such selective killing of leukemic cells can also be achieved by inhibiting
cyclin D associated kinase activity in mouse and human T-ALL models. Inhibition of cyclin D-kinase activity
represents a highly-selective anticancer strategy that specifically targets cancer cells without significantly
affecting normal tissues.INTRODUCTION
The proliferation of mammalian cells is driven by the core cell
cycle machinery operating in the cell nucleus. The key compo-
nents of this machinery are proteins called cyclins, which bind,
activate, and provide substrate specificity to cyclin-dependent
kinases (CDKs). Cyclin-CDK complexes phosphorylate cellular
proteins, thereby driving cell cycle progression (Malumbres
and Barbacid, 2009).Significance
D-cyclins are recipients of many oncogenic signals, and are o
consequences of an acute and global inhibition of D-cyclins in
largely dispensable for normal physiology of adult animals, but
that acute cyclin D1- or D3-inhibition causes tumor cell senesc
is expected to be highly specific in shutting off cancer prog
demonstration that inhibition of cyclin D-CDK kinase selectiv
a potential therapeutic strategy in patients bearing these mali
438 Cancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc.Among all cyclin classes, D-type cyclins are of particular
importance to the cancer field, as they represent the ultimate
recipients of many oncogenic pathways (Deshpande et al.,
2005; Fu et al., 2004; Musgrove et al., 2011). This family is
composed of cyclins D1, D2, and D3, which show substantial
amino acid sequence similarity, and are expressed in an over-
lapping, redundant fashion in all proliferating cell types (Mus-
grove et al., 2011). D-cyclins bind and activate CDK4 and
CDK6; cyclin D-CDK4 and D-CDK6 complexes phosphorylateften overexpressed in human cancers. This study tests the
vivo, in a living mouse. We found that cyclins D1 or D3 are
they are essential for tumor maintenance. We demonstrated
ence or apoptosis. Hence, therapeutic targeting of D-cyclins
ression, without significantly affecting normal tissues. Our
ely kills mouse and human leukemic cells in vivo suggests
gnancies.
Cancer Cell
D-Cyclins in Tumor Maintenancethe retinoblastoma tumor suppressor protein, pRB, and pRB-like
p107 and p130 proteins, leading to activation or derepression of
E2F transcription factors. E2Fs then induce several target genes
that are required for entry of cells into the DNA synthesis (S)
phase (Trimarchi and Lees, 2002). In addition, cyclin D-CDK4
and D-CDK6 complexes play a second, noncatalytic function
in G1 phase progression through sequestration of cell cycle
inhibitors p27Kip1 and p21Cip1, which leads to activation of
CDK2-containing complexes (Sherr and Roberts, 2004).
Amplificationof individual cyclinDgenesandoverexpressionof
their encoded proteins were documented in a large proportion of
human cancers. For example, cyclin D1 is overexpressed in the
majority of breast cancer cases,whereasoverexpression of cyclin
D3 is observed inmany lymphoidmalignancies (Deshpande et al.,
2005; Fu et al., 2004; Musgrove et al., 2011). A comprehensive
analysis of many human cancer types revealed that the gene en-
coding cyclinD1 represents the secondmost frequently amplified
locus in thehumancancergenome (Beroukhimetal., 2010).More-
over, in many human cancers overexpression of D-type cyclins
takes place in the absence of any detectable genomic alterations
(Deshpande et al., 2005; Fu et al., 2004; Musgrove et al., 2011).
It was initially assumed that individual D-type cyclins are
required for proliferation of normal, nontransformed cells. How-
ever, we and others found that knockout mice lacking individual
D-cyclins are viable, and display only minor phenotypes, re-
vealing that these proteins are dispensable for development
of the overwhelming majority of organs (Sherr and Roberts,
2004). In contrast, particular D-cyclins were shown to be essen-
tial for tumor initiation in vivo in the specific compartments. For
example, mice lacking cyclin D1 are resistant to ErbB2-driven
mammary adenocarcinomas, while cyclin D3 null animals are
refractory to Notch1-driven T-ALL (Bowe et al., 2002; Landis
et al., 2006; Sicinska et al., 2003; Yu et al., 2001).
These analyses established an essential requirement for D-cy-
clins in tumor initiation. An important unresolved question is
whether these proteins are also required for tumor maintenance,
andwhether their ablation inmice that already developed tumors
would have an effect on tumor progression.
Another critical question for therapeutic targeting of D-cyclins
is what would be the consequence of an acute shutdown of
individual D-cyclins in the whole animal. Knockout mice lacking
particular D-cyclins displayed only minor phenotypes, but these
mice developed from the very beginning in the absence of a
cyclin D-protein. It is well-established that ‘‘constitutive,’’ germ-
line knockout animals often activate compensatory mechanisms
(Lin et al., 2008; Sage et al., 2003), whereas an acute shutdown
of a protein in an adult animal may have much more profound
consequences.
To address these questions, we developed mouse models
that allowed us to inducibly shut off cyclin D function in the whole
animal. Using thesemodels, we acutely and ubiquitously ablated
expression of cyclin D1 or D3 in adult mice that developed
different types of tumors.
RESULTS
Acute Ablation of Cyclin D1 in Adult Mice
In order to determine the consequence of an acute and global
ablation of cyclin D1 in adult mice, we generated conditionalCcyclin D1 knockout (D1F/F) animals (Figures S1A–S1C available
online).Wedetermined that cyclin D1F/Fmice developed normally
and displayed no phenotypic abnormalities, consistent with the
expectation that the ‘‘floxed’’ cyclin D1 allele is functionally wild-
type. We interbred cyclin D1F/F and cyclin D1/mice and gener-
ated heterozygous cyclin D1F/ animals that were used in the
analyses described below. These cyclin D1F/mice were pheno-
typically normal, as expected from the normal appearance of
cyclinD1+/heterozygotes (Fantl et al., 1995;Sicinski et al., 1995).
In order inducibly ablate cyclin D1 expression in adult mice, we
crossed cyclin D1F/ mice with Esr1-Cre animals. The latter
strain ubiquitously expresses tamoxifen-inducible Cre recombi-
nase. Administration of tamoxifen to Esr1-Cre mice activates
Cre, leading to global deletion of the floxed sequences in mouse
organs (Hayashi and McMahon, 2002).
Adult cyclin D1F//Esr1-Cre mice were injected with tamox-
ifen, and efficient deletion of cyclin D1 in several organswas veri-
fied by semiquantitative PCR (Figure S1D). We then observed
the animals for 1 year, without noting any obvious abnormalities
or premature lethality. The mice displayed normal biochemical
parameters in the peripheral blood, which were periodically
monitored (Figures S1E and S1F and data not shown). Hence,
acute ablation of cyclin D1 in adult mice had no detectable
impact on the animals’ health, suggesting that cyclin D1 is largely
dispensable for normal physiology of adult animals.
Acute Ablation of Cyclin D1 in Adult Females Bearing
ErbB2-Driven Mammary Carcinomas
We next asked what would be the consequence of an acute and
global ablation of cyclin D1 in mice bearing ErbB2-driven
mammary carcinomas. We used MMTV-ErbB2 mice that over-
express ErbB2 (HER2) oncogene in their mammary epithelium
(Muller et al., 1988). Female MMTV-ErbB2 mice develop mam-
mary adenocarcinomas with a median latency of 30–40 weeks
(Yu et al., 2001). We interbred cyclin D1F/, Esr1-Cre, and
MMTV-ErbB2 mice and generated cyclin D1F//Esr1-Cre/
MMTV-ErbB2 females. Once these animals developed palpable
breast tumors, we injected them with tamoxifen, thereby trig-
gering cyclin D1 deletion in the whole animal, including in their
breast cancers (Figure 1A). We found that ablation of cyclin D1
halted breast cancer progression. For controls, we used cyclin
D1F/+/Esr1-Cre/MMTV-ErbB2 females, whose tumors continued
to grow following tamoxifen challenge (Figure 1B). Conse-
quently, at the time of sacrifice, the animals’ overall tumor
burden was significantly lower in cyclin D1F/-/Esr1-Cre/MMTV-
ErbB2 females (Figures 1B, S1G, and S1H).
Staining of tumor sections for Ki-67, a marker of proliferation,
revealed a strongly reduced fraction of cells expressing Ki-67 in
cyclin D1-deleted tumors, indicating that cyclin D1 shutdown
crippled proliferation of breast cancer cells in vivo (Figures
S1I and S1J). Strikingly, we observed that cyclin D1 ablation
also triggered senescence of breast cancer cells, as evidenced
by wide-spread staining of tumor cells for senescence-associ-
ated (SA)-b-galactosidase (Figures 1C and 1D) and trimethylated
lysine 9 of histone H3 (H3K9-Me3, Figure S1K). These results
indicate that the continued presence of cyclin D1 is required to
maintain growth of ErbB2-overexpressing breast cancers, by
driving tumor cell proliferation and by protecting tumor cells
from senescence.ancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc. 439
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Figure 1. Acute Ablation of Cyclin D1Blocks
Tumor Progression and Triggers Senes-
cence in ErbB2-Driven Tumors
(A) Schematic representation of the experimental
design.
(B) Total tumor burden per mouse in cyclin D1F/+/
Esr1-Cre/MMTV-ErbB2 (D1D /+) and in D1F//Esr1-
Cre/MMTV-ErbB2 (D1D /) mice. Deletion of cyclin
D1 was induced (by tamoxifen administration)
upon detection of palpable tumors; mice were
sacrificed after 6 weeks. In the top panel, each
dot represents the total tumor burden (g) for
a given mouse upon sacrifice, horizontal lines
represent mean values. Lower panel: mean total
tumor burden (g) per mouse. Error bars represent
SD, n = 10.
(C) Representative SA-b-galactosidase staining
of sections of ErbB2-driven mammary tumors
following acute cyclin D1 shutdown (cyclin D1D /),
or in control animals (cyclin D1D/+). Scale bar
represents 50 mm.
(D) Mean percentage of SA-b-galactosidase-
positive area in tumor sections. For each section,
three independent areas were scanned and
quantified using software from Aperio Technolo-
gies. Error bars represent SEM.
(E) Total tumor burden per animal inMMTV-ErbB2
mice treated daily with vehicle only (VO) or PD
0332991 (PD, 150 mg/kg body weight) for 6 weeks
after detection of palpable tumors. Upper panel
shows tumor burden for each mouse, lower panel
shows mean values ± SD, n = 7.
(F) Representative SA-b-galactosidase staining of
sections of ErbB2-driven mammary carcinomas
frommice treated with vehicle only or PD 0332991
for 6 weeks after detection of palpable tumors.
Scale bar represents 50 mm.
(G) Mean percentage of area staining positive for
SA-b-galactosidase, analyzed as in (D). Error bars
represent SEM.
See also Figure S1.
Cancer Cell
D-Cyclins in Tumor MaintenanceInhibition of Cyclin D-Cdk Kinase Activity in Adult
Females Bearing ErbB2-Driven Mammary Tumors
We next asked whether inhibition of cyclin D-associated kinase
activity would have the same impact as an acute cyclin D1
ablation. To address this issue, we monitored a group of
MMTV-ErbB2 females for breast cancer occurrence. As soon
as breast tumors were detected, we started treating mice with
PD 0332991, a specific and potent inhibitor of cyclin D-CDK4
and D-CDK6 kinases (Fry et al., 2004). We found that inhibition
of cyclin D-associated kinase activity essentially phenocopied
an acute cyclin D1 ablation, namely it halted progression of
breast cancers, and it triggered tumor cell senescence (Figures
1E–1G, S1L, and S1M), without having any overt effect on the
animals’ health (data not shown). Neither cyclin D1 ablation nor440 Cancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc.PD 0332991 treatment had any effect on
the apoptotic rate of breast cancer cells
(Figure S1N).
Collectively, these analyses revealed
that cyclin D1 and cyclin D1-associated
kinase are largely dispensable for thephysiology of adult animals, but they are essential for mainte-
nance of ErbB2-driven breast cancers.
Molecular Analyses of ErbB2-Driven Breast Cancers
In order to gain some understanding of the observed antisenes-
cence function of cyclin D1-associated kinase in breast cancers
in vivo, we first focused on the pRB/ E2F pathway. Hypophos-
phorylated (active) pRB protein was shown to enforce the senes-
cent state by permanently silencing expression of E2F target
genes, such as cyclin E1, cyclin A2, or Dhfr (Chicas et al.,
2010; Narita et al., 2003; Dean et al., 2010). We found that
administration of PD 0332991 to breast cancer-bearing ani-
mals resulted in a strong inhibition of pRB phosphorylation in
breast cancer cells in vivo (Figure S1O). This led to decreased
Cancer Cell
D-Cyclins in Tumor Maintenanceexpression of E2F target genes, including the genes whose
silencing was implicated to play a role in the senescence
program (Figure S1P). We conclude that inhibition of E2F activity
likely contributes to cancer cell senescence in vivo.
We recently showed that cyclin D1-CDK4 kinase phosphory-
lates, stabilizes, and activates FOXM1 transcription factor (An-
ders et al., 2011), which plays an important role in protecting
cancer cells from senescence (Li et al., 2008a; Park et al.,
2009). Moreover, treatment of in vitro cultured human cancer
cells with PD 0332991 destabilized FOXM1 and led to pRB-inde-
pendent cancer cell senescence (Anders et al., 2011). Analyses
of breast tumors from PD 0332991-treated mice revealed signif-
icantly decreased levels of FOXM1 protein in cancer cells in vivo
(Figure S1Q). We also established that this led to significantly
reduced levels of FOXM1 transcriptional targets (Figure S1R).
It is likely that this inhibition of FOXM1 activity contributes to
senescence of breast cancer cells in vivo, upon PD 0332991-
administration to cancer-bearing mice. It should be noted,
however, that because we ablated cyclin D1, or inhibited cyclin
D1-associate kinase in the entire animal (not only in tumor cells)
we cannot exclude that noncell autonomous mechanisms con-
tributed to inhibition of tumor progression.
Ablation of Cyclin D3 in Adult Mice
Another instance of a specific requirement for a particular D-cy-
clin in tumor initiation is the reliance of T cell acute lymphoblastic
leukemia (T-ALL) formation on cyclin D3. We previously showed
that cyclin D3/mice are refractory toNotch1-driven T-ALL (Si-
cinska et al., 2003). To determine whether T-ALL cells also
require this cyclin for tumor maintenance, we generated condi-
tional cyclin D3 knockout (D3F/F) mice (Figures S1S–S1U).
We crossed cyclin D3F/F and Esr1-Cre mice and obtained cy-
clin D3F/F/Esr1-Cre animals. We challenged adult cyclin D3F/F/
Esr1-Cre mice with tamoxifen, verified efficient deletion of the
floxed cyclin D3 alleles in multiple organs (Figure S1V), and
observed mice for 1 year. We found no obvious abnormalities
upon cyclin D3 ablation throughout the entire observation
period, including normal biochemical parameters in the periph-
eral blood, which were periodically monitored (Figure S1E).
Because cyclin D3/ mice displayed hematopoietic abnor-
malities (Sicinska et al., 2003, 2006; Cooper et al., 2006), we
also crossed cyclin D3F/F mice with Mx1-Cre animals. The latter
strain allows a very efficient inducible deletion of the floxed
sequences in the hematopoietic cells, following administration
of polyI-polyC (pI-pC) (Ku¨hn et al., 1995) (Figure S2A). We found
that an acute shutdown of cyclin D3 in the hematopoietic line-
ages of cyclin D3F/F/Mx1-Cre animals essentially phenocopied
the abnormalities observed in constitutive cyclin D3 null mice.
Specifically, cyclin D3D/D/Mx1-Cre animals displayed very small
thymi containing significantly reduced numbers of double-
positive CD4+CD8+ thymocytes (Figures S2B and S2C). Anal-
yses of peripheral blood revealed modestly decreased red and
white blood cell counts (Figures S2D–S2F), again resembling
the abnormalities found in cyclin D3/ animals (Sicinska et al.,
2006). Altogether, these observations revealed that an acute
shutdown of cyclin D3 recapitulated the phenotype of cyclin
D3 null mice, but it did not cause any additional major abnormal-
ities, indicating that cyclin D3 is largely dispensable for the health
of adult animals.CAblation of Cyclin D3 in T-ALL
We next asked what would be the impact of an acute shutdown
of cyclin D3 for development and maintenance of T cell acute
lymphoblastic leukemia. As before, we utilized a mouse model
of Notch1-driven T-ALL, as the majority of human T-ALL cases
contain activating lesions in the Notch1 pathway (Weng et al.,
2004). We collected bone marrow cells from cyclin D3F/F/
Mx1-Cre+ or D3F/F/Mx1-Cre mice, flow-sorted hematopoietic
progenitor cells (HPC), transduced HPC with a retrovirus encod-
ing activated Notch1 (Notch1 intracellular domain, Notch1-ICD)
and GFP, and injected the transduced HPC into the bloodstream
of sublethally irradiated C57BL/6 wild-type recipient mice (Fig-
ure 2A). It is well established that the recipient animals develop
T-ALL following this procedure. The first abnormal, GFP-positive
CD4+CD8+ cells appear in the peripheral blood after 2 weeks,
mice develop multiple T cell tumors after 6 weeks, leading to the
animals’ death within 10–12 weeks (Li et al., 2008b; Chiang et al.,
2006).
Two weeks after bone marrow transplantation (BMT), when
abnormal GFP+ cells appeared in the peripheral blood, we chal-
lenged the recipient mice with pI-pC to ablate cyclin D3 expres-
sion in the transplanted cells. Unexpectedly, we found that the
GFP+ cells essentially disappeared from the peripheral blood
following cyclin D3 shutdown (Figures 2B and 2C). Further ob-
servation of animals revealed that whereas control mice (trans-
duced with cyclin D3F/F/Mx1-Cre-negative HPC) developed
T cell tumors and died within 11 weeks, six out of seven mice
that sustained acute cyclin D3 deletion remained leukemia-free
and healthy throughout the observation period (Figure 2D). We
found that in the single experimental mouse that succumbed
to T-ALL, tumors arose from the residual cells containing unde-
leted cyclin D3 alleles (Figure S3A). The remaining six mice were
eventually sacrificed after 30 weeks, and the absence of infil-
trating leukemic cells in their organs was verified by detailed
histopathological analysis (Figure S3B). Hence, an acute abla-
tion of cyclin D3 blocked development of Notch1-driven T-ALL
in vivo.
In the analyses described above, we deleted cyclin D3 at
an early time-point of T-ALL development. To investigate the
requirement for cyclin D3 in the maintenance of T-ALL tumors,
we next switched off cyclin D3 expression (by pI-pC administra-
tion) at 6.5 weeks post-BMT, after the animals had developed
tumors (Figure 3A). We then collectedmajor organs and enumer-
ated the presence of infiltrating GFP+ tumor cells, by FACS.
Strikingly, we found that an acute ablation of cyclin D3 led to
a strong reduction in the number of tumor cells (Figures 3B
and 3C; data not shown). Long-term observation of animals re-
vealed that ablation of cyclin D3 led to a significant extension
of the animals’ survival (Figure 3D).We verified that tumorswhich
eventually arose in these animals contained GFP+ cells with un-
deleted cyclin D3F alleles (Figure S3C). Collectively, these anal-
yses established that cyclin D3 is required for maintenance of
Notch1-driven T-ALL in vivo, and that an acute ablation of cyclin
D3 leads to disappearance of malignant cells.
Cell Cycle Arrest and Tumor Cell Apoptosis Following
Ablation of Cyclin D3
To examine the cellular mechanisms by which cyclin D3 abla-
tion inhibits Notch1-ICD-induced T-ALL progression, we firstancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc. 441
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Figure 2. Acute Ablation of Cyclin D3 in
a Mouse Model of Notch1-ICD-Driven
T Cell Acute Lymphoblastic Leukemia
(A) Schematic representation of the experimental
design. After T-ALL formation in the recipient
mice, cyclin D3 ablation was induced at 2 weeks
post-BMT.
(B) Representative FACS profiles showing per-
centage of Notch1-ICD-overexpressing GFP+
cells in peripheral blood right after completion of
pI-pC administration (started 2 weeks post-BMT)
to cyclin D3F/F/Mx1-Cre+(D3D/D) or D3F/F/Mx1-
Cre (D3F/F) mice. SSC, side scatter.
(C) Mean percentages of GFP+ cells in peripheral
blood ofmice treated as in (B). Error bars represent
SD, n = 7.
(D) Kaplan-Meier analysis of survival time in each
group, n = 7.
See also Figure S2.
Cancer Cell
D-Cyclins in Tumor Maintenanceexamined cell cycle distribution of splenic tumor cells following
an acute shutdown of cyclin D3. We observed a reduction of
cells in the S phase and an increase of G0/G1 cells (Figures
S4A–S4C). We next asked whether the rapid disappearance of
T-ALL cells upon cyclin D3 ablation might be caused by tumor
cell apoptosis. To test this, we stained the GFP+ leukemic cells
from the peripheral blood, as well as tumor cells that infiltrated
spleens, with Annexin V/7-AAD, and analyzed by FACS. We
detected wide-spread apoptosis of peripheral blood leukemic
cells and of tumor cells following cyclin D3 ablation (Figures
4A–4D). TUNEL staining of tumor sections confirmed tumor
cell apoptosis (Figure 4E). These analyses revealed that cyclin
D3 is required to maintain survival of T-ALL cells, and that abla-
tion of cyclin D3 triggers tumor cell apoptosis.
Tumor Cell Apoptosis following Inhibition of Cyclin
D-Cdk Kinase
We wished to determine whether inhibition of cyclin D3-associ-
ated kinase activity would have the same impact as an acute
cyclin D3 ablation. To address this, mice were injected with
wild-type hematopoietic progenitor cells that were transduced
with a virus expressing Notch1-ICD and GFP, leading to T-ALL
development. Daily treatment with PD 0332991 was started
when GFP+ cells were detected in the peripheral blood (2 weeks
posttransplantation), or after mice had developed T cell tumors
(6.5 weeks posttransplantation). Once the treatment was initi-
ated, we observed a strong reduction in the number of leukemic
cells in the peripheral blood and of tumor cells infiltrating the
peripheral organs (Figures 5A and 5B; data not shown). Contin-
uous long-term treatment resulted in a dramatic improvement
of survival rates in both groups, with the majority of animals re-
maining healthy at 40 weeks post-BMT (Figures 5C and 5D).
Importantly, we verified that treatment of tumor cells with PD
0332991 inhibited cell cycle progression and triggered tumor442 Cancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc.cell apoptosis, thereby mimicking the
effect of an acute cyclin D3 ablation
(Figures 5E, 5F, S5A, and S5B data not
shown). Moreover, combined administra-
tion of pI-pC (to induce deletion of cyclinD3) plus PD 0332991 to cyclin D3F/F/Mx1-Cre mice did not
increase the tumor apoptotic rate above that seen upon cyclin
D3 ablation alone, confirming that the effects of PD 0332991
are mediated by inhibiting cyclin D3 activity (Figure S5C). No
senescence of T-ALL cells was observed following PD
0332991 treatment (Figure S5D). Collectively, these findings
indicate that cyclin D3-Cdk kinase is required for T-ALL mainte-
nance, by driving cell proliferation and by protecting tumor cells
from the apoptotic death.
Analyses of Human Leukemic Cells In Vitro and In Vivo
We next asked whether inhibition of cyclin D-associated
kinase activity in human leukemic cells would also trigger
apoptosis. We chose human T-ALL cell lines KOPTK1,
DND41, MOLT-16, and RPMI-8402, which are known to harbor
activating mutations in the NOTCH1 gene (NOTCH1-ICD-posi-
tive) (O’Neil et al., 2007). We treated cells in vitro with PD
0332991, stained them with Annexin V/7-AAD, and analyzed
by FACS. We observed that inhibition of cyclin D-CDK kinase
triggered cell cycle arrest and apoptosis of human T-ALL cells
(Figures 6A, 6B, S6A, and S6B; data not shown). No senes-
cence of T-ALL cells was observed after PD 0332991 treatment
(Figure S6C).
Similar analysis of an additional 20 human leukemic cell lines
(including NOTCH1-ICD-negative T-ALL, B cell ALL, and others)
revealed that PD 0332991 treatment did not cause substantial
increase in the apoptotic rate in these cell lines (Figure S6D;
data not shown). This, together with our observations that inhibi-
tion of cyclin D3 activity killedNotch1-ICD-positive mouse T-ALL
tumor cells (Figures 4 and 5), suggests that cyclin D3-CDK ac-
tivity is specifically required for survival of T-ALL cells with acti-
vated Notch1 pathway.
Intriguingly, comparison of the levels of D-cyclins and
CDKs between four NOTCH1-ICD-positive and negative human
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Figure 3. Cyclin D3 Is Required for Mainte-
nance of Notch1-ICD-Driven T-ALL In Vivo
(A) Schematic representation of the experimental
design. After T-ALL formation in the recipientmice,
cyclin D3 ablation was induced at 6.5 weeks post-
BMT.
(B) Representative FACS analysis showing per-
centage of Notch1-ICD-overexpressing GFP+
cells in spleens right after completion of pI-pC
administration (started 6.5 weeks post-BMT) in
cyclin D3F/F/Mx1-Cre+ (D3D/D) or D3F/F/Mx1-Cre
(D3F/F) mice. SSC, side scatter.
(C) Mean percentages of GFP+ cells in spleens
of mice treated as in (B). Error bars represent
SD, n = 4.
(D) Kaplan-Meier analysis of survival time in each
group, n = 6.
See also Figure S3.
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D-Cyclins in Tumor MaintenanceT-ALL lines indicated that the former express significantly higher
levels of cyclin D3 (and cyclin D2) and cyclin D3-CDK6
complexes (Figures S6E and S6F). It is possible that NOTCH1
activation increases the levels of D-cyclins in T-ALL cells,
thereby making these cells ‘‘addicted’’ to cyclin D-CDK kinase
for tumor cell survival.
To test the response of human NOTCH1-ICD-positive T-ALL
cells to cyclin D-CDK inhibition in an in vivo setting, we engi-
neered the human T-ALL cell lines KOPTK1 and DND41 to stably
express firefly luciferase. Engineered human leukemic cells were
injected intravenously into immunocompromised mice, and
bioluminescence imaging was used to assess the distribution
and burden of leukemic disease. Recipient mice died within
5–7 weeks due to widely disseminated T cell leukemia.
To determine the acute effects of CDK4/6 inhibition, mice with
disseminated KOPTK1 and DND41 leukemia were treated for
5–7 days with PD 0332991. As expected, leukemic burden
increased in vehicle-treated mice (Figures 7A and 7C). In con-
trast, treatment with PD 0332991 either resulted in a nearly
5-fold reduction in tumor burden (KOPTK1 cells, Figure 7A) or
blunted this increase (DND41, Figure 7C). We collected periph-
eral blood and bone marrow cells from PD 0332991 treated
animals, and analyzed the proportion of apoptotic human
T-ALL cells by Annexin V/7-AAD staining followed by FACS.
Treatment of tumor-bearing mice with PD 0332991 induced
significant apoptosis in both KOPTK1 (Figure 7B) and DND41
(Figure 7D) xenografts in vivo without having any overt effect
on the animals’ health (Figure S7; data not shown).
To determine the therapeutic efficacy of CDK4/6 inhibi-
tion, we treated mice bearing established human T-ALL xeno-
grafts with PD 0332991. Long-term daily treatment with PD
0332991 resulted in suppression of leukemia progression as
determined by bioluminescence imaging (Figures 7E, 7F, 7H,
and 7I), and resulted in a highly significant prolongation inCancer Cell 22, 438–451,survival for both KOPTK1 (Figure 7G)
and DND41 (Figure 7J) xenografted ani-
mals. Collectively, these findings suggest
that inhibition of cyclin D-associated
kinase activity in patients with NOTCH1-
positive T-ALL might represent an attrac-tive therapeutic approach, as it may lead to selective killing of
leukemic cells.
Molecular Analyses of T-ALL Cells and Breast Cancer
Cells
The studies described above revealed that T-ALL cells respond
to inhibition of cyclin D-CDK4/6 kinase by undergoing cell cycle
arrest and cell death. In order to understand the molecular basis
of these phenomena, we first focused on the pRB / E2F
pathway. We observed that treatment of T-ALL cells with PD
0332991 resulted in the appearance of hypophosphorylated
(active) pRB species (Figures S5A, S5B, S6A, and S6B). Inhibi-
tion of cyclin D3 function led to diminished E2F transcriptional
activity, as evidenced by decreased levels of several E2F tran-
scriptional targets, including genes involved in G1 and S phase
progression (Figure S4C). We conclude that inhibition of the
pRB / E2F pathway is likely responsible for cell cycle arrest
of T-ALL cells following PD 0332991 treatment.
The pRB/ E2F pathway was shown to be also involved in
controlling cell survival (Ianari et al., 2009; Young and Longmore,
2004). E2Fs can play both pro-survival and pro-apoptotic roles,
depending on cellular context (Chen et al., 2009; Chong et al.,
2009). In the developing mouse retinas, E2Fs were shown to
play a pro-survival function by inducing expression of p53-
deacetylating enzymes. Ablation of E2Fs in retinal cells was
demonstrated to cause strong hyperacetylation of p53, leading
to p53 activation and p53-dependent cell death (Chen et al.,
2009). However, we found that cyclin D3-CDK kinase likely
does not operate through this mechanism in T-ALL cells. First,
we established that PD 0332991 treatment did not overtly
change p53 acetylation levels in T-ALL cells (Figure S5E). More-
over, cyclin D-CDK4/6 inhibition also triggered apoptosis of
T-ALL cell lines expressing mutant p53: MOLT-16, DND-41, and
RPMI-8402 (http://www.sanger.ac.uk/genetics/CGP/CellLines/)October 16, 2012 ª2012 Elsevier Inc. 443
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Figure 4. Cyclin D3 Ablation Triggers Apoptosis of Notch1-ICD-Driven T-ALL Cells
Mice receivedNotch1-ICD-GFP-transduced cyclin D3F/F/Mx1-Cre+ (D3D/D) or D3F/F/Mx1-Cre (D3F/F) bone marrow cells, and were treated five times with pI-pC,
starting at 6.5 weeks following BMT.
(A) Representative FACS profiles of peripheral blood stained for Annexin V/7-AAD and gated on GFP+ cells.
(B) Mean percentages of apoptotic (Annexin V+) cells in peripheral blood (gated on GFP+ cells) and analyzed as in (A). Error bars represent SD, n = 4.
(C) Representative FACS profiles of cells from the spleen stained for Annexin V/7-AAD and gated on GFP+.
(D) Mean percentages of apoptotic (Annexin V+) cells from spleens (gated on GFP+ cells) and analyzed as in (C). Error bars represent SD, n = 4.
(E) TUNEL staining of spleen sections. Scale bar represents 50 mm.
See also Figure S4.
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D-Cyclins in Tumor Maintenance(Figure 6), indicating that the apoptosis following cyclin D-CDK4/6
inhibition can be p53-independent.
Given a differential response to PD 0332991 treatment of
T-ALL cells (cell cycle arrest and apoptosis) versus breast cancer
cells (cell cycle arrest and senescence, but no apoptosis), we
decided to compare the response of these two tumor types to
cyclin D-CDK4/6 inhibition at a molecular level. To this end, we
treated in vitro cultured human T-ALL cell line KOPTK1 and
mouse breast cancer cells derived from MMTV-ErbB2 tumor
(V720 cells) (Yu et al., 2006) with PD 0332991. We then analyzed
gene expression at a genome-wide level using microarrays.
Comparison of T-ALL and breast cancer cell expression
profiles revealed three distinct gene expression groups (Fig-444 Cancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc.ure 8A; Tables S1–S4). The first group comprised of genes that
change their expression upon PD 0332991 treatment both in
T-ALL and in breast cancer cells. We observed a strong enrich-
ment for ‘‘cell cycle’’ genes by gene ontology analysis in this
group (Table S2). Analysis of all cell cycle genes that were signif-
icantly regulated by PD 0332991 treatment indicated that the
majority of them were downregulated (Figure 8B), which likely
explains the observed cell cycle arrest.
The second group comprised of genes that, upon PD 0332991
treatment, change their expression in T-ALL, but not in breast
cancer cells (Figure 8A). This group showed strong enrichment
for ‘‘apoptosis’’ genes by gene ontology analysis (Table S3).
Analysis of all apoptosis-related genes that were significantly
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Figure 5. Pharmacological Inhibition of
Cdk4/6 Activity in Notch1-ICD-Driven T-ALL
Mice received Notch1-ICD-GFP-transduced
C57BL/6 wild-type bone marrow cells, and were
fed daily with either vehicle only (VO) or Cdk4/6
inhibitor, PD 0332991 (PD, 100–150 mg/kg body
weight).
(A) PD 0332991 treatment was started at
6.5 weeks post-BMT. Shown are representative
FACS profiles depicting percentage of GFP+ cells
in peripheral blood after 7 days of PD 0332991
administration. SSC, side scatter.
(B) Mean percentages of GFP+ cells in peripheral
blood, in mice treated as in (A). Error bars repre-
sent SD, n = 7.
(C and D) Kaplan-Meyer survival curves. (C)
Treatment was started at 2 weeks post-BMT
(following detection of GFP+ cells in peripheral
blood), n = 10 mice per group. (D) Treatment
started at 6.5 weeks post-BMT, after animals had
developed tumors, n = 10 mice per group.
(E and F) Splenocytes from vehicle treated mori-
bund mice were cultured in vitro and treated with
vehicle only (VO) or 1 mM of PD 0332991 (PD) for
4 days. Cells were then stained for Annexin V/7-
AAD, and analyzed by FACS.
(E) Shown is a representative FACS profile of
Annexin V/7-AAD staining gated on GFP+ splenic
tumor cells.
(F) Mean percentage of apoptotic (Annexin V+)
tumor cells following treatment with vehicle only or
1 mM of PD. Error bars represent SD, n = 4.
See also Figure S5.
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D-Cyclins in Tumor Maintenanceregulated in KOPTK1 cells by PD 0332991 treatment revealed
that those genes displayed both up- or downregulation after
treatment (Figure 8C). Visual inspection of these genes revealed
that cyclin D-CDK4/6 inhibition led to a strong downregulation of
BIRC5/Survivin, and resulted in an upregulation of components
of the extrinsic apoptotic pathway (TNF,CASP8,CASP10), upre-
gulation of pro-apoptotic BIM, as well an upregulation of GZMA
and GZMB (Figure 8D).
The third group (Figure 8A) contained genes, which change
their expression in breast cancer cells, but not in T-ALL
cells. This group showed enrichment for ‘‘cell division’’ genes
as well for ‘‘TGF-b,’’ consistent with the well-established role
of TGF-b in cellular senescence (Kuilman and Peeper, 2009)
(Table S4).
Collectively these analyses suggest that inhibition of cyclin
D-CDK4/6 kinase in NOTCH1-positive T-ALL cells triggers a
transcriptional apoptotic program, thereby causing death of
tumor cells.
DISCUSSION
The causative role of cyclin D overexpression in the pathogen-
esis of human cancers has been very well documented. Amplifi-
cation and rearrangements of the cyclin D1 gene were observed
in nearly 100% of mantle cell lymphomas, a substantial fraction
of multiple myelomas, and in several other cancer types in-
cluding breast, squamous cell, pancreatic, endometrial, and
lung carcinomas. Also genes encoding cyclin D2 or D3 are
frequently amplified in human lymphoid malignancies and inCtesticular cancers (Deshpande et al., 2005; Fu et al., 2004; Mus-
grove et al., 2011). Overexpression of cyclin D proteins, which
results from these genomic abnormalities, is believed to repre-
sent an early, causative event in tumor formation (Chaganti
and Houldsworth, 2000; Deshpande et al., 2005; Musgrove
et al., 2011). For example, in breast cancers, cyclin D1 overex-
pression represents one of the earliest oncogenic lesions, seen
already in ductal carcinoma in situ (Weinstat-Saslow et al.,
1995). Consistent with the role of overexpressed D-cyclins as
drivers of the oncogenic process, transgenic mice engineered
to overexpress cyclin D1 in mammary glands are prone to
mammary carcinomas (Wang et al., 1994). Also, targeted over-
expression of cyclin D1 in B lymphocytes was shown to coop-
erate with the Myc oncogene in triggering B cell lymphomas
(Bodrug et al., 1994; Lovec et al., 1994).
Analyses of knockout mice lacking individual D-cyclins sup-
ported an essential role for these proteins in tumor initiation.
Thus, mice lacking cyclin D1, or its catalytic partner, Cdk4, are
either resistant, or show significantly reduced sensitivity to
Ras- and ErbB2-driven breast tumors, depending on the genetic
background and type of transgene used (Bowe et al., 2002;
Reddy et al., 2005; Yu et al., 2001, 2006; Zhang et al., 2011).
Loss of cyclin D1 also renders mice resistant to rhabdoid tumors
arising in Ini1 heterozygotes, decreases intestinal tumorigenesis
in ApcMin background, and reduces incidence of Ras-driven skin
papillomas (Hulit et al., 2004; Robles et al., 1998; Tsikitis et al.,
2005). Cyclin D2 null mice show decreased incidence of ovarian
and testicular tumors (Burns et al., 2003), whereas mice lacking
cyclin D3 or Cdk6, are resistant to Notch1-driven T cell acuteancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc. 445
AB
Figure 6. Pharmacological Inhibition of
CDK4/6 Kinase Triggers Apoptosis of
Human T-ALL Cell Lines
Human T-ALL cell lines were cultured and treated
with vehicle only (VO) or 1 mM of PD 0332991 (PD)
for 4 days, stained for Annexin V/7-AAD and
analyzed by FACS.
(A) Shown are representative FACS profiles of
KOPTK1, DND41, MOLT-16, and RPMI-8402 cells
stained with Annexin V/7-AAD.
(B) Quantification of the apoptotic (Annexin V+)
cells, analyzed as above. Shown are mean values.
Error bars represent SD, n = 4.
See also Figure S6.
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D-Cyclins in Tumor Maintenancelymphoblastic leukemias, or to lymphomagenesis triggered by
activated Akt (Hu et al., 2009; Sicinska et al., 2003).
All these observations point to the requirement for a D-cyclin
in oncogenic transformation. However, in order to validate ther-
apeutic targeting of D-cyclins in cancer treatment one must
establish whether the continued presence of these proteins is
required to maintain tumor progression. Another critically impor-
tant question is what would be the consequence of an acute
and global ablation of a D-type cyclin in a living animal. To
address these issues, we developed mouse strains that allowed
us to globally shut down expression of individual D-cyclins in
mice that developed different types of tumors. We report here
that an acute ablation of cyclin D1 in adult mice bearing446 Cancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc.ErbB2-driven breast cancers halted
tumor progression, and triggered senes-
cence of cancer cells, without compro-
mising the animals’ health. We also found
that an acute ablation of cyclin D3
blocked T-ALL progression by triggering
tumor cell apoptosis. Similar effects
were seen upon inhibition of cyclin
D-Cdk kinase in vivo, by PD 0332991
administration to tumor-bearing animals.
Collectively, these results reveal that indi-
vidual D-cyclins are not required for
normal mouse physiology, but they are
absolutely essential for tumor mainte-
nance. Hence, by targeting particular
D-cyclins, or by inhibiting their associated
kinases, one can selectively kill tumor
cells, or irreversibly arrest their prolifera-
tion by triggering tumor cell senescence,
without affecting normal tissues. It re-
mains to be seen whether ablating all
three D-cyclins would have any conse-
quences in normal adult animals.
Our results are consistent with recent
findings of Puyol et al. (2010) demon-
strating that an acute shutdown of Cdk4
in a mouse model of K-Ras-driven non-
small cell lung cancers triggered senes-
cence of tumor cells in vivo. Together
with our results, these findings indicate
that cyclin D1-CDK4 antisenescencefunction likely operates in several cancer types. On the other
hand, Zhang et al. (2011) recently reported that MMTV-ErbB2
breast tumor cells, after two rounds of in vitro and in vivo
passaging, no longer require cyclin D1 for proliferation, due to
upregulation of cyclin D3. These results indicate that analyses
of serially passaged cell lines need to be treated with caution,
and should be verified in vivo using intact tumors, as in the
work of Puyol et al. (2010) and in this study.
It remains to be determined what makes cancer cells so
distinctly dependent on individual D-cyclins. One possibility
is that the molecular mechanism of cell cycle progression
operates differently in cancer cells versus in normal cells. More-
over, cyclin D-CDK4/6 complexes may play additional, cell
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Figure 7. Effects of Pharmacological Inhibition of CDK4/6 on Human T-ALL In Vivo
Human KOPTK1-Luc+ or DND41-Luc+ cells were engrafted by tail vein injection into NSG mice and treated daily with vehicle only (VO) or PD 0332991 (PD,
150 mg/kg body weight).
(A) Animals with established KOPTK1-Luc+ leukemia were treated daily, for 5 days, with vehicle or PD 0332991. Tumor burden is expressed as relative biolu-
minescence, normalized to the baseline bioluminescence on treatment day 1. Shown are mean values, error bars represent SEM.
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Figure 8. Response of KOPTK1 T-ALL Cells and V720 Breast Cancer Cells to Inhibition of Cyclin D-CDK Kinase
(A) KOPTK1 and V720 cells were treatedwith PD 0332991 (PD) or vehicle (VO) for 48 hr and 24 hr, respectively. Experiment was done in triplicate. Genes that show
changes in expression levels after PD treatment were selected based on an absolute fold-change >1.5, absolute mean difference >50, and p value <0.05, and
were classified into three groups: genes with altered expression levels in both cell types (Group 1), in KOPTK1 cells only (Group 2), or in V720 cells only (Group 3).
Each row corresponds to one gene and is normalized across the row.
(B) Heatmap images representing relative expression levels of cell cycle-related genes that showed significant expression change after PD treatment in KOPTK1
cells (top) or V720 cells (bottom).
(C) A heatmap image representing relative expression levels of apoptosis-related genes that showed significant expression change after PD treatment in KOPTK1
cells.
(D) Expression levels of seven apoptosis-related genes in KOPTK1 cells. Shown are mean values ± SD, n = 3 per group.
See also Tables S1–S4.
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D-Cyclins in Tumor Maintenancecycle-independent functions in cancer cells, by protecting these
cells from oncogene-induced senescence, or by maintaining
tumor cell survival. Indeed, cyclin D-CDK kinase was shown to(B) After 5 days of treatment, peripheral blood and bone marrow were collected fro
determined by FACS analysis of Annexin V/7-AAD staining, gated on human CD4
Error bars represent SD.
(C) Animals with established DND41-Luc+ leukemia were treated daily, for 7 day
minescence, normalized to the baseline bioluminescence on treatment day 1. Sh
(D) After 7 days of treatment, peripheral blood and bone marrow were collected fr
determined by FACS analysis of Annexin V/7-AAD staining, gated on human CD4
Error bars represent SD.
(E) Bioluminescence imaging of representative vehicle and PD 0332991 treated K
(F) Total body bioluminescence (photons s1 ROI1) in vehicle and PD 0332991 t
tumor burden. Shown are mean values, error bars represent SEM.
(G) Kaplan-Meier survival curves of KOPTK1-Luc+ recipients treated with vehicle
(H) Bioluminescence imaging of representative vehicle and PD 0332991 treated
(I) Total body bioluminescence (photons s1 ROI1) in vehicle and PD 0332991 t
tumor burden. Shown are mean values, error bars represent SEM.
(J) Kaplan-Meier survival curves of DND41-Luc+ recipients treated with vehicle o
See also Figure S7.
448 Cancer Cell 22, 438–451, October 16, 2012 ª2012 Elsevier Inc.protect cells against senescence, by acting through the retino-
blastoma protein (Chicas et al., 2010; Dean et al., 2010; Ruas
et al., 2007) and through FOXM1 (Anders et al., 2011). It is likelymKOPTK1-Luc+ xenografted animals, and apoptosis of human leukemic cells
5+ cells. Graphs represent mean percentages of apoptotic (Annexin V+) cells.
s, with vehicle or PD 0332991. Tumor burden is expressed as relative biolu-
own are mean values, error bars represent SEM.
om DND41-Luc+ xenografted animals, and apoptosis of human leukemic cells
5+ cells. Graphs represent mean percentages of apoptotic (Annexin V+) cells.
OPTK1-Luc+ xenografted animals.
reated recipients of KOPTK1-Luc+ cells was monitored over time to determine
or PD 0332991.
DND41-Luc+ xenografted animals.
reated recipients of DND41-Luc+ cells was monitored over time to determine
nly or PD 0332991. n = 8 for all groups.
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not in normal tissues, which renders these tumors uniquely
sensitive to cyclin D-CDK inhibition.
In contrast to the impact of cyclinD1 inhibition inbreast tumors,
where it caused tumor cell senescence, we found that the shut-
down of cyclin D3 in lymphoid tumors triggered apoptosis.
Importantly, we found that cyclin D3-CDK inhibition also resulted
in killing of human T-ALL cells in vitro and in vivo. Intriguingly, this
effect seems to be specific toNOTCH1-ICD-positive T-ALL, sug-
gesting a ‘‘synthetic lethal’’ interaction between activation of the
Notch1 pathway and cyclin D-CDK kinase inhibition in leukemic
cells. Although the exact molecular mechanism of the observed
cell death remains to be determined, our analyses suggest that
inhibition of cyclin D-CDK4/6 kinase activity in NOTCH1-ICD-
positive T-ALL cells triggers a transcriptional apoptotic program,
which likely contributes to killing of tumor cells.
Altogether, our study demonstrates that in addition to the well-
established roles of overexpressed D-cyclins in tumor initiation,
the presence of D-cyclins is essential for tumor maintenance.
Our results show that inhibition of cyclin D-kinase activity repre-
sents a highly selective anticancer strategy that specifically
targets cancer cellswithout significantly affecting normal tissues.
EXPERIMENTAL PROCEDURES
Full experimental procedures and any associated references are available in
the Supplemental Experimental Procedures.
Generation of Conditional Cyclin D1F/F and D3F/F Mice
Please see Supplemental Experimental Procedures for details. All animal
procedures conformed to the relevant regulatory standards, guidelines, and
regulations, and were approved by the Dana Farber Cancer Institute Animal
Care and Users Committee. Genotyping and deletion analysis of floxed or
deleted cyclin D1 and D3 alleles were performed with primers: D1-50 (50-GA
GTTTTCCGGGTGCGTT-30), D1-30 (50-CTGTGGTGTCGCTGACA-30), D1-D
(50-GGCAGTAGCAAGATCTGTTA-30) and D3-50 (50-CTGCGTTCTGTCCCTTT
CCTT-30 ), D3-30 (50-CGCGATAGACACAGGAACCA-30), and D3-D (50-CCA
GACTGGAGCCAGAGATAA-30) by predenaturation of genomic DNA at 94C
for 5 min, followed by 33 cycles of amplification: 94C for 30 s, 60C for
30 s, 72C for 30 s, and a final extension step at 72C for 10 min. The sizes
of PCR products are: for cyclin D1wt = 180 base pairs (bp), D1F = 420 bp,
D1D = 476 bp, D3wt = 210 bp, D3F = 500 bp, and D3D = 450 bp. Cyclin D1F/F
mice were bred with cyclin D1/ (Sicinski et al., 1995), Esr1-Cre, and
MMTV-ErbB2 animals. Cyclin D3F/F mice were bred with Esr1-Cre and Mx1-
Cre animals. Mx1-Cre, MMTV-ErbB2, and Esr1-Cre mice were from Jackson
Laboratory.
Acute Ablation of Cyclins D1 or D3 and PD 0332991 Treatment
Esr1-Cre expressing mice were injected intraperitoneally with 4-hydroxyta-
moxifen (Sigma) 0.225 mg/g of body weight on alternate days. To inhibit cyclin
D-Cdk kinase,micewere fed daily with PD 0332991, 150mg/kg of bodyweight
by gastric gavage; every 2 weeks the daily dose was lowered to 100 mg/kg for
2–3 days. Control mice were treated with vehicle (10% 0.1N HCl, 10%Crema-
phor EL, 20% PEG300, 60% 50 mM citrate buffer pH 4.5) 10 ml/kg by gastric
gavage.Mx1-Cre expressingmice were injected intraperitoneally with 2.5 mg/g
body weight of polyinosinic-polycytidylic acid on alternate days (pI-pC,
Amersham).
Flow Cytometry Analysis and Sorting
Cells were stained with antibodies against CD4 andCD8 (BDBiosciences). For
cell cycle analyses, mice were intraperitoneally injected with 1–2 mg BrdU and
sacrificed after 2hr. Tissues were harvested and analyzed with BrdU-Flow kit
using either anti-BrdU antibody conjugated to phycoerythrin (PE) or fluores-
cein isothiocyanate (FITC) (BD Biosciences). Annexin V/7-AAD staining wasCperformed on fresh cells according to the manufacturer’s specifications
(ApoScreen, Southern Biotech). Cells from human T-ALL xenotransplants
were stained with anti-human CD45 antibody (Biolegend). Alternatively cells
were fixed, permeabilized, and stained with phycoerythrin (PE)-mouse anti-
phospho pRbS780 antibody (BD Biosciences) or isotype IgG1 control and
analyzed by FACS. All data acquisition was performed on LSRII, Fortessa
and Facscan and analyzed using Cell Quest and FACSDiva software (BD
Biosciences). Sorting was conducted on Moflow or FACSaria sorters (BD
Biosciences).
In Vitro Analyses of Leukemic Cells
Spleens were collected from moribund vehicle-treated recipients of Notch1-
ICD- and GFP-expressing tumor cells and cultured for 4 days in RPMI sup-
plemented with 10% fetal calf serum (Sigma) and 10 mM glutamine in the
presence of 1mMPD 0332991 or vehicle. Human T-ALL cell lines were cultured
as described in Supplemental Experimental Procedures. Cells were then
stained as described above and analyzed by flow cytometry.
Human T-ALL Xenografts
KOPTK1 and DND41 cells were stably transduced with the FUW-Luc-
mCherry-puro lentivirus (Kimbrel et al., 2009) to generate KOPTK1-Luc+ and
DND41-Luc+ cells. To establish orthotopic xenografts, 2 3 106 engineered
cells were injected intravenously via the lateral tail vein into NOD-SCID-
IL2Rgnull (NSG) mice. Bioluminescence imaging was performed by injecting
mice with 75 mg/kg of D-Luciferin (Promega, Madison, WI), followed by
imaging on an IVIS Spectrum (Caliper Life Sciences, Hopkinton, MA). Total
body bioluminescence was determined by quantifying photon flux through
standardized regions of interest using the Living Images software package
(Caliper Life Sciences). Mice with established disease, defined by increasing
bioluminescence, were entered onto treatment with either PD 0332991
150 mg/kg by gastric gavage, or vehicle 10 ml/kg by gastric gavage. Mice
were imaged at the indicated time points, and were sacrificed when they
showed signs of distress.
Statistical Calculations
Statistical significance was calculated by log rank (Mantel-Cox) test for the
survival curves and two-way ANOVA test for the bioluminescence data.
All other p values were calculated by Student’s unpaired t test.
ACCESSION NUMBERS
Expression data can be found at http://www.ncbi.nlm.nih.gov/geo/ under
superseries accession number GSE40514.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, four tables, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2012.09.015.
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